De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet. 2008;372(9656):2152–61..
Survival analysis part II: multivariate data analysis – an introduction to concepts and methods. Br J Cancer. 2003;89(3):431–6., , , .
Survival Analysis: A Self-learning Text. 2nd edn: Springer; 2005., .
A convenient approximation of life expectancy (the “DEALE”). I. Validation of the method. Am J Med. 1982;73(6):883–8., , .
Kidney failure or cancer. Should immunosuppression be continued in a transplant patient with malignant melanoma?Med Decis Making. 1984;4(1):82–107., , .
United States Life Tables, 2008. National Vital Statistics Reports. Hyattsville, MD: National Center for Health Statistics; 2012..
Life expectancy biases in clinical decision modeling. Med Decis Making. 1995;15(2):158–69., .
Recent developments in decision-analytic modelling for economic evaluation. Pharmacoeconomics. 2006;24(11):1043–53..
The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. Health Technol Assess. 2004;8(11):iii, 1–91., , , , .
Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332(21):1418–24., , , et al.
Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73–83., , , .
Calibrating models in economic evaluation: a seven-step approach. Pharmacoeconomics. 2011;29(1):35–49., , , et al.
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol. 2007;166(2):137–50., , , et al.
Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. Value Health. 2011;14(5):700–4., , , et al.
Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches. Pharmacoeconomics. 2012;30(2):119–26., , , et al.
Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics. 2010;28(11):995–1000., , , et al.
Calibration of disease simulation model using an engineering approach. Value Health. 2009;12(4):521–9., , .
Bayesian calibration of microsimulation models. J Am Stat Assoc. 2009;104(488):1338–50., , .
Calibration methods used in cancer simulation models and suggested reporting guidelines. Pharmacoeconomics. 2009;27(7):533–45., , , , .
Mathematical models in the evaluation of health programmes. Lancet. 2011;378(9790):515–25., , , , .
Apparent and internal validity of a Monte Carlo-Markov model for cardiovascular disease in a cohort follow-up study. Med Decis Making. 2006;26(2):134–44., , , et al.
Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the Rotterdam ischemic heart disease and stroke computer simulation (RISC) model. BMC Med. 2012;10:158., , , et al.
The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr. 2006;(36):37–47., , , et al.
Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration. Stat Methods Med Res. 2004;13(6):507–24., , , .
Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med. 2000;133(9):665–75., .
Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94(8):2043–53., , .
Bayesian calibration of a natural history model with application to a population model for colorectal cancer. Med Decis Making. 2011;31(4):625–41., , .
Bayesian calibration of computer models. J R Stat Soc: Series B (Statistical Methodology). 2001;63(3):425–64., .
Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151(8):538–45., , .
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making. 2012;32(5):733–43., , , et al.
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Making. 2012;32(5):678–89., , , et al.
The recent decline in mortality from coronary heart disease, 1980–1990. The effect of secular trends in risk factors and treatment. JAMA. 1997;277(7):535–42., , , et al.
Pharmacogenomics of hepatitis C and decision analysis: a glimpse into the future. Hepatology. 2002;36(1):252–4..
Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149(9):659–69., , , et al.
Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92., , , et al.
Analytic choices in economic models of treatments for rheumatoid arthritis: What makes a difference?Med Decis Making. 2005;25(5):520–33., , .
The CHD challenge: comparing four cost-effectiveness models. Value Health. 2011;14(1):53–60., , , et al.
Uncertainty and validation of health economic decision models. Health Econ. 2010;19(1):43–55., .